Aura Biosciences, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

AURA$7.65-0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Additional · Accumulated · Total
Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’
	Shares	Amount	Capital	Deficit	Income (Loss)	Equity
Balance, December 31, 2024	49,998,279	$—	$525,934	$(374,227)	$263	151,970
Stock-based compensation expense	—	—	14,317	—	—	14,317
Employee Stock Purchase Plan Issuance	28,125	—	164	—	—	164
Vesting of restricted stock	532,401	—	—	—	—	—
Stock option exercises	238,045	—	1,010	—	—	1,010
Unrealized loss on marketable securities	—	—	—	—	(179)	(179)
Issuance of common stock through follow-on offering, net of issuance costs of $384	11,735,565	—	46,517	—	—	46,517
Issuance of pre-funded warrants through follow-on offering, net of issuance costs of $117	—	—	14,156	—	—	14,156
Issuance of common stock warrants through follow-on offering, net of issuance costs of $76	—	—	9,254	—	—	9,254
Issuance of common stock under ATM facility, net of issuance costs of $452	1,055,362	—	6,054	—	—	6,054
Currency translation adjustment	—	—	—	—	(186)	(186)
Other	—	—	27	—	—	27
Net loss	—	—	—	(106,191)	—	(106,191)
Balance, December 31, 2025	63,587,777	—	617,433	(480,418)	(102)	136,913
Additional · Accumulated · Total
Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’
	Shares	Amount	Capital	Deficit	Income	Equity
Balance, December 31, 2023	49,350,788	$—	$512,617	$(287,308)	$539	225,848
Stock-based compensation expense	—	—	11,722	—	—	11,722
Employee Stock Purchase Plan Issuance	24,477	—	177	—	—	177
Vesting of restricted stock	310,245	—	—	—	—	—
Stock option exercises	312,769	—	1,418	—	—	1,418
Unrealized loss on marketable securities	—	—	—	—	(271)	(271)
Other	—	—	—	—	(5)	(5)
Net loss	—	—	—	(86,919)	—	(86,919)
Balance, December 31, 2024	49,998,279	—	525,934	(374,227)	263	151,970

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.